CRISPR Therapeutics AG (CRSP): Depreciation & Amortization
$19.48M
Year ended 2025-12-31
$18.69M
Trailing 12 months to 2026-06-30
-6.9%
3-year compound annual growth
+16.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.48M | +1.1% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $19.26M | -2.9% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $19.84M | -17.9% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $24.17M | +34.6% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $17.95M | +95.5% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $9.18M | +94.4% | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $4.72M | +34.3% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $3.52M | +16.4% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $3.02M | +226.9% | 2020-02-12, From 2017-01-01 |
| 2016-12-31 | $925.0K | +628.3% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $127.0K | +234.2% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $38.0K | n/a | 2017-03-10, From 2014-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $19.48M | +1.1% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $537.0K | -62.8% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $1.45M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $7.32M | +19.5% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $73.0K | -1.4% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $2.99M | +9.8% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $12.90M | -32.0% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $117.1K | +2.8% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.42M | -13.8% |
Compare CRSP, SRZN, CGON, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗